184 related articles for article (PubMed ID: 21400476)
1. Prognostic factors in patients with hepatitis C virus infection and systemic vasculitis.
Terrier B; Semoun O; Saadoun D; Sène D; Resche-Rigon M; Cacoub P
Arthritis Rheum; 2011 Jun; 63(6):1748-57. PubMed ID: 21400476
[TBL] [Abstract][Full Text] [Related]
2. Causes and predictive factors of mortality in a cohort of patients with hepatitis C virus-related cryoglobulinemic vasculitis treated with antiviral therapy.
Landau DA; Scerra S; Sene D; Resche-Rigon M; Saadoun D; Cacoub P
J Rheumatol; 2010 Mar; 37(3):615-21. PubMed ID: 20110523
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup study of thirty-two patients.
Terrier B; Saadoun D; Sène D; Sellam J; Pérard L; Coppéré B; Karras A; Blanc F; Buchler M; Plaisier E; Ghillani P; Rosenzwajg M; Cacoub P
Arthritis Rheum; 2009 Aug; 60(8):2531-40. PubMed ID: 19644879
[TBL] [Abstract][Full Text] [Related]
4. PegIFNα/ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis.
Saadoun D; Resche Rigon M; Pol S; Thibault V; Blanc F; Pialoux G; Karras A; Bazin-Kara D; Cazorla C; Vittecoq D; Musset L; Peltier J; Decaux O; Ziza JM; Lambotte O; Cacoub P
J Hepatol; 2015 Jan; 62(1):24-30. PubMed ID: 25135864
[TBL] [Abstract][Full Text] [Related]
5. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
Cacoub P; Lidove O; Maisonobe T; Duhaut P; Thibault V; Ghillani P; Myers RP; Leger JM; Servan J; Piette JC
Arthritis Rheum; 2002 Dec; 46(12):3317-26. PubMed ID: 12483738
[TBL] [Abstract][Full Text] [Related]
6. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
Papastergiou V; Stampori M; Lisgos P; Pselas C; Prodromidou K; Karatapanis S
Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):798-805. PubMed ID: 23395996
[TBL] [Abstract][Full Text] [Related]
7. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
8. PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
Cacoub P; Saadoun D; Limal N; Sene D; Lidove O; Piette JC
Arthritis Rheum; 2005 Mar; 52(3):911-5. PubMed ID: 15751068
[TBL] [Abstract][Full Text] [Related]
9. Human cytomegalovirus infection inhibits response of chronic hepatitis-C-virus-infected patients to interferon-based therapy.
Bader el-Din NG; Abd el-Meguid M; Tabll AA; Anany MA; Esmat G; Zayed N; Helmy A; el-Zayady AR; Barakat A; el-Awady MK
J Gastroenterol Hepatol; 2011 Jan; 26(1):55-62. PubMed ID: 21175794
[TBL] [Abstract][Full Text] [Related]
10. Health-related quality of life and severity of fatigue in HIV/HCV co-infected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirin.
Mandorfer M; Payer BA; Scheiner B; Breitenecker F; Aichelburg MC; Grabmeier-Pfistershammer K; Rieger A; Trauner M; Peck-Radosavljevic M; Reiberger T
Liver Int; 2014 Jan; 34(1):69-77. PubMed ID: 23890125
[TBL] [Abstract][Full Text] [Related]
11. Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C.
Ogawa E; Furusyo N; Shimizu M; Ihara T; Hayashi T; Harada Y; Toyoda K; Murata M; Hayashi J
Antivir Ther; 2015; 20(2):185-92. PubMed ID: 24941012
[TBL] [Abstract][Full Text] [Related]
12. A review of the treatment of chronic hepatitis C virus infection in cirrhosis.
Vezali E; Aghemo A; Colombo M
Clin Ther; 2010 Dec; 32(13):2117-38. PubMed ID: 21316532
[TBL] [Abstract][Full Text] [Related]
13. Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy.
Lange CM; Kutalik Z; Morikawa K; Bibert S; Cerny A; Dollenmaier G; Dufour JF; Gerlach TJ; Heim MH; Malinverni R; Müllhaupt B; Negro F; Moradpour D; Bochud PY;
Hepatology; 2012 Apr; 55(4):1038-47. PubMed ID: 22095909
[TBL] [Abstract][Full Text] [Related]
14. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis.
Mira JA; Rivero-Juárez A; López-Cortés LF; Girón-González JA; Téllez F; de los Santos-Gil I; Macías J; Merino D; Márquez M; Ríos-Villegas MJ; Gea I; Merchante N; Rivero A; Torres-Cornejo A; Pineda JA;
Clin Infect Dis; 2013 Jun; 56(11):1646-53. PubMed ID: 23429381
[TBL] [Abstract][Full Text] [Related]
15. Sustained virological response to pegylated interferon and ribavirin in patients with genotype 3 HCV cirrhosis.
Butt AS; Mumtaz K; Aqeel I; Shah HA; Hamid S; Jafri W
Trop Gastroenterol; 2009; 30(4):207-12. PubMed ID: 20426280
[TBL] [Abstract][Full Text] [Related]
16. Liver fibrosis progression in HIV-HCV-coinfected patients treated with distinct antiretroviral drugs and impact of pegylated interferon/ribavirin therapy.
Fernández-Montero JV; Barreiro P; Vispo E; Labarga P; Sánchez-Parra C; de Mendoza C; Treviño A; Soriano V
Antivir Ther; 2014; 19(3):287-92. PubMed ID: 24192598
[TBL] [Abstract][Full Text] [Related]
17. [Hepatitis C virus-associated cryoglobulinemic vasculitis: A 20-year experience with treatment].
Ignatova TM; Kozlovskaya LV; Gordovskaya NB; Chernova OA; Milovanova SY; Novikov PI; Nekrasova TP; Beketova TV; Mukhin NA
Ter Arkh; 2017; 89(5):46-52. PubMed ID: 28631698
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of double filtration plasmapheresis with pegylated interferon/ribavirin therapy for intractable chronic hepatitis C patients and hepatitis C patients with combined liver cirrhosis by HBV, leading to early viral elimination.
Ohara T; Oteki T; Suzuki T; Suzuki M; Matsuzaki Y
Hepatogastroenterology; 2011; 58(105):133-6. PubMed ID: 21510300
[TBL] [Abstract][Full Text] [Related]
19. Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study.
Giordanino C; Bugianesi E; Smedile A; Ciancio A; Abate ML; Olivero A; Pellicano R; Cassader M; Gambino R; Bo S; Ciccone G; Rizzetto M; Saracco G
Am J Gastroenterol; 2008 Oct; 103(10):2481-7. PubMed ID: 18702647
[TBL] [Abstract][Full Text] [Related]
20. Impact of pegylated interferon alfa-2a and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open-label series.
Mukherjee S; Lyden E
Hepatogastroenterology; 2006; 53(70):561-5. PubMed ID: 16995462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]